{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:19:51Z","timestamp":1753888791061,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Funda\u00e7\u00e3o para Ci\u00eancia e Tecnologia","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"GESCAT"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02984-1","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T03:13:16Z","timestamp":1713669196000},"page":"805-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Primary thromboprophylaxis in cancer outpatients \u2013 real-world evidence"],"prefix":"10.1007","volume":"57","author":[{"given":"Joana","family":"Liz-Pimenta","sequence":"first","affiliation":[]},{"given":"Val\u00e9ria","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Grama\u00e7a","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Rato","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Menezes","sequence":"additional","affiliation":[]},{"given":"Mafalda","family":"Baleiras","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Guedes","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Reis","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Guedes","sequence":"additional","affiliation":[]},{"given":"Rosa","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Barbosa","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"2984_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-20315-3_1","volume":"179","author":"G Soff","year":"2019","unstructured":"Soff G (2019) Thrombosis and hemostasis in cancer. Scope of the problem and overview. Cancer Treat Res 179:1\u20139","journal-title":"Cancer Treat Res"},{"issue":"1","key":"2984_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA et al (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8(1):1\u201318","journal-title":"Nat Rev Dis Primers"},{"key":"2984_CR3","doi-asserted-by":"crossref","unstructured":"Khorana AA et al (2021) Healthcare costs of patients with cancer stratified by Khorana score risk levels. J Med Econ 24(1):866\u2013873","DOI":"10.1080\/13696998.2021.1948681"},{"key":"2984_CR4","doi-asserted-by":"crossref","unstructured":"Karamouzis MV et al (2021) The impact of thromboprophylaxis on the survival of patients with advanced pancreatic cancer. The pancreatic cancer and tinzaparin (PaCT) study. Cancers 13(12):2884","DOI":"10.3390\/cancers13122884"},{"issue":"6","key":"2984_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","volume":"125","author":"AA Khorana","year":"2010","unstructured":"Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125(6):490\u2013493","journal-title":"Thromb Res"},{"issue":"12","key":"2984_CR6","doi-asserted-by":"publisher","first-page":"e013839","DOI":"10.1136\/bmjopen-2016-013839","volume":"6","author":"PN Apenteng","year":"2016","unstructured":"Apenteng PN et al (2016) Patients\u2019 perceptions and experiences of the prevention of hospital-acquired thrombosis: a qualitative study. BMJ Open 6(12):e013839","journal-title":"BMJ Open"},{"issue":"6","key":"2984_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","volume":"21","author":"A Falanga","year":"2023","unstructured":"Falanga A, Marchetti M (2023) Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost 21(6):1397\u20131408","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2984_CR8","first-page":"4902","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood J Am Soc Hematol 111(10):4902\u20134907","journal-title":"Blood J Am Soc Hematol"},{"key":"2984_CR9","doi-asserted-by":"crossref","unstructured":"Yan A-R et al (2021) Risk factors and prediction models for venous thromboembolism in ambulatory patients with lung cancer. Healthcare 9(6):778","DOI":"10.3390\/healthcare9060778"},{"issue":"10","key":"2984_CR10","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"5","key":"2984_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","volume":"22","author":"CA Cella","year":"2017","unstructured":"Cella CA et al (2017) Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist 22(5):601\u2013608","journal-title":"Oncologist"},{"issue":"3","key":"2984_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","volume":"7","author":"M Verso","year":"2012","unstructured":"Verso M et al (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291\u2013292","journal-title":"Intern Emerg Med"},{"issue":"18","key":"2984_CR13","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","volume":"33","author":"U Pelzer","year":"2015","unstructured":"Pelzer U et al (2015) Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 33(18):2028\u20132034","journal-title":"J Clin Oncol"},{"key":"2984_CR14","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.tru.2021.100075","volume":"5","author":"F Moik","year":"2021","unstructured":"Moik F et al (2021) Risk assessment models of cancer-associated thrombosis-potentials and perspectives. Thrombosis Update 5:100075","journal-title":"Thrombosis Update"},{"issue":"2","key":"2984_CR15","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1634\/theoncologist.2019-0510","volume":"25","author":"J Godinho","year":"2020","unstructured":"Godinho J et al (2020) ONKOTEV score as a predictive tool for thromboembolic events in pancreatic cancer-a retrospective analysis. Oncologist 25(2):e284\u2013e290","journal-title":"Oncologist"},{"issue":"1","key":"2984_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11239-010-0522-0","volume":"31","author":"G Stashenko","year":"2011","unstructured":"Stashenko G et al (2011) Prophylaxis for venous thromboembolism: guidelines translated for the clinician. J Thromb Thrombolysis 31(1):122\u2013132","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2984_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","volume":"22","author":"AJ Munoz Martin","year":"2020","unstructured":"Munoz Martin AJ et al (2020) SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol 22(2):171\u2013186","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"2984_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"8","key":"2984_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711\u2013719","journal-title":"N Engl J Med"},{"issue":"8","key":"2984_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720\u2013728","journal-title":"N Engl J Med"},{"issue":"8","key":"2984_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMe1816060","volume":"380","author":"G Agnelli","year":"2019","unstructured":"Agnelli G (2019) Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. N Engl J Med 380(8):781\u2013783","journal-title":"N Engl J Med"},{"key":"2984_CR22","doi-asserted-by":"publisher","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","volume":"22 Suppl 6","author":"M Mandal\u00e0","year":"2011","unstructured":"Mandal\u00e0 M et al (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 22 Suppl 6:vi85-92","journal-title":"Ann Oncol"},{"issue":"8","key":"2984_CR23","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1007\/s00520-022-07096-1","volume":"30","author":"S Xynogalos","year":"2022","unstructured":"Xynogalos S et al (2022) Can thromboprophylaxis build a link for cancer patients undergoing surgical and\/or chemotherapy treatment? The MeTHOS cohort study. Support Care Cancer 30(8):6973\u20136984","journal-title":"Support Care Cancer"},{"issue":"1","key":"2984_CR24","first-page":"e000610","volume":"5","author":"F Moik","year":"2020","unstructured":"Moik F, Pabinger I, Ay C (2020) How I treat cancer-associated thrombosis. ESMO Open 5(1):e000610","journal-title":"ESMO Open"},{"issue":"10","key":"2984_CR25","first-page":"1181","volume":"19","author":"MB Streiff","year":"2021","unstructured":"Streiff MB et al (2021) Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(10):1181\u20131201","journal-title":"J Natl Compr Canc Netw"},{"key":"2984_CR26","doi-asserted-by":"crossref","unstructured":"Christopoulou A et al (2022) Prophylaxis of cancer\u2011associated venous thromboembolism with low\u2011molecular\u2011weight heparin\u2011tinzaparin: real world evidence. Oncol Lett 23(4):115","DOI":"10.3892\/ol.2022.13235"},{"issue":"9","key":"2984_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","volume":"48","author":"A Maraveyas","year":"2012","unstructured":"Maraveyas A et al (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48(9):1283\u20131292","journal-title":"Eur J Cancer"},{"issue":"4","key":"2984_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2984_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u201347","journal-title":"Eur J Cancer"},{"key":"2984_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood-2023-172815","volume":"142","author":"CA Cella","year":"2023","unstructured":"Cella CA et al (2023) Comparison of Khorana vs. Onkotev predictive score to individualize anticoagulant prophylaxis in ambulatory patients with cancer. Blood 142:661","journal-title":"Blood"},{"key":"2984_CR31","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/S0049-3848(20)30402-3","volume":"191","author":"GH Lyman","year":"2020","unstructured":"Lyman GH, Kuderer NM (2020) Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. Thromb Res 191:S79\u2013S84","journal-title":"Thromb Res"},{"issue":"04","key":"2984_CR32","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1055\/s-0038-1675577","volume":"02","author":"V Pach\u00f3n","year":"2018","unstructured":"Pach\u00f3n V et al (2018) Cancer-associated thrombosis: beyond clinical practice guidelines\u2014A multidisciplinary (SEMI\u2013SEOM\u2013SETH) expert consensus. TH Open 02(04):e373\u2013e386","journal-title":"TH Open"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02984-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:13:36Z","timestamp":1720516416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02984-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02984-1","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"9 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of Hospital Center of Tr\u00e1s-os-Montes and Alto Douro (CES. 489\/2018, 20th December 2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Patients signed an informed written consent according to the principles of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"J.-L.P. received funding from LEO Pharma to conduct this investigation. The funder had no role in the collection, analysis, and interpretation of data, writing of the manuscript, or in the decision to submit the paper for publication. The remaining authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}